Literature DB >> 35386741

Refractory eosinophilic fasciitis successfully treated with infliximab: A case report.

Paulina Śmigielska1, Justyna Czarny1, Jacek Kowalski2, Aleksandra Wilkowska1, Roman J Nowicki1.   

Abstract

Eosinophilic fasciitis is a rare connective tissue disease of unknown etiology. Therapeutic options include high-dose corticosteroids and other immunosuppressive drugs. We present a typical eosinophilic fasciitis case, which did not respond to first-line treatment, but improved remarkably after infliximab administration. This report demonstrates that in case of initial treatment failure, infliximab might be a relatively safe and effective way of eosinophilic fasciitis management.
© The Author(s) 2021.

Entities:  

Keywords:  Eosinophilic fasciitis; infliximab; monoclonal antibody; scleroderma-like disorders

Year:  2021        PMID: 35386741      PMCID: PMC8892936          DOI: 10.1177/23971983211004399

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  9 in total

1.  Infliximab effective in steroid-dependent juvenile eosinophilic fasciitis.

Authors:  N Tzaribachev; U Holzer; J Schedel; V Maier; R Klein; J Kuemmerle-Deschner
Journal:  Rheumatology (Oxford)       Date:  2008-04-16       Impact factor: 7.580

2.  Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases.

Authors:  Dinesh Khanna; Harsh Agrawal; Philip J Clements
Journal:  Rheumatology (Oxford)       Date:  2010-03-22       Impact factor: 7.580

Review 3.  Eosinophilic fasciitis: From pathophysiology to treatment.

Authors:  Hironobu Ihn
Journal:  Allergol Int       Date:  2019-03-22       Impact factor: 5.836

4.  Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses.

Authors:  Anna Drosou; Robert S Kirsner; Esperanza Welsh; Tory P Sullivan; Francisco A Kerdel
Journal:  J Cutan Med Surg       Date:  2003-09-24       Impact factor: 2.092

Review 5.  Eosinophilic Fasciitis: an Updated Review on Diagnosis and Treatment.

Authors:  Daniel R Mazori; Alisa N Femia; Ruth Ann Vleugels
Journal:  Curr Rheumatol Rep       Date:  2017-11-04       Impact factor: 4.592

6.  Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.

Authors:  Sa Rang Kim; Alexandra Charos; William Damsky; Peter Heald; Michael Girardi; Brett A King
Journal:  JAAD Case Rep       Date:  2018-04-30

7.  Eosinophilic fasciitis (Shulman's disease): review and comparative evaluation of seven patients.

Authors:  Joana Urzal; Miriam Cimbron; Teresa Mendonça; Fátima Farinha
Journal:  Reumatologia       Date:  2019-04-29

8.  Tumour necrosis factor-α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-κB and AP-1.

Authors:  Hannu Kankaanranta; Pinja Ilmarinen; Xianzhi Zhang; Ian M Adcock; Aleksi Lahti; Peter J Barnes; Mark A Giembycz; Mark A Lindsay; Eeva Moilanen
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

9.  Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission.

Authors:  Rechelle Tull; William D Hoover; Jacqueline F De Luca; William W Huang; Joseph L Jorizzo
Journal:  Drugs Context       Date:  2018-10-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.